3.20
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.32
Aprire:
$3.3
Volume 24 ore:
1.70M
Relative Volume:
1.78
Capitalizzazione di mercato:
$227.34M
Reddito:
-
Utile/perdita netta:
$-117.81M
Rapporto P/E:
-1.7021
EPS:
-1.88
Flusso di cassa netto:
$74.30M
1 W Prestazione:
-0.31%
1M Prestazione:
+0.95%
6M Prestazione:
-72.60%
1 anno Prestazione:
-18.99%
Omeros Corporation Stock (OMER) Company Profile
Nome
Omeros Corporation
Settore
Industria
Telefono
206-676-5000
Indirizzo
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Confronta OMER con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
OMER
Omeros Corporation
|
3.20 | 227.34M | 0 | -117.81M | 74.30M | -1.88 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-06-10 | Iniziato | H.C. Wainwright | Buy |
2024-12-23 | Iniziato | D. Boral Capital | Buy |
2024-11-14 | Iniziato | Rodman & Renshaw | Buy |
2022-12-08 | Downgrade | UBS | Buy → Neutral |
2022-11-08 | Downgrade | BofA Securities | Neutral → Underperform |
2022-06-08 | Downgrade | BofA Securities | Buy → Neutral |
2021-10-08 | Downgrade | JP Morgan | Neutral → Underweight |
2021-10-01 | Downgrade | Maxim Group | Buy → Hold |
2021-10-01 | Downgrade | Wedbush | Neutral → Underperform |
2021-09-27 | Iniziato | JP Morgan | Neutral |
2021-02-01 | Iniziato | UBS | Buy |
2020-10-20 | Iniziato | BofA Securities | Buy |
2020-08-21 | Reiterato | H.C. Wainwright | Buy |
2020-08-14 | Reiterato | Maxim Group | Buy |
2019-05-06 | Iniziato | Cantor Fitzgerald | Overweight |
2018-07-12 | Iniziato | Seaport Global Securities | Buy |
2018-03-23 | Downgrade | Wedbush | Outperform → Neutral |
2018-03-05 | Downgrade | Needham | Buy → Hold |
2017-11-08 | Iniziato | H.C. Wainwright | Buy |
2017-05-11 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
2017-03-17 | Reiterato | Maxim Group | Buy |
2017-03-17 | Reiterato | Needham | Buy |
2016-11-16 | Reiterato | Wedbush | Outperform |
2016-11-10 | Reiterato | Needham | Buy |
2016-08-10 | Reiterato | Maxim Group | Buy |
2016-06-03 | Iniziato | Cantor Fitzgerald | Buy |
2016-03-02 | Reiterato | Needham | Buy |
2016-02-29 | Reiterato | Wedbush | Outperform |
2015-11-11 | Reiterato | Needham | Buy |
2015-08-18 | Reiterato | WBB Securities | Strong Buy |
2015-08-10 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Omeros Corporation Borsa (OMER) Ultime notizie
Ratios Revealed: Decoding Omeros Corporation (OMER)’s Financial Health - DWinneX
Omeros Co. (NASDAQ:OMER) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
What is HC Wainwright’s Forecast for Omeros FY2025 Earnings? - Defense World
HC Wainwright Predicts Omeros’ Q2 Earnings (NASDAQ:OMER) - Defense World
Omeros (NASDAQ:OMER) Now Covered by Analysts at HC Wainwright - Defense World
Cantor Fitzgerald Comments on Omeros FY2026 Earnings - Defense World
Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision - Benzinga
Trend Tracker for (OMER) - news.stocktradersdaily.com
Omeros (OMER) Receives Buy Rating from HC Wainwright & Co. | OME - GuruFocus
Omeros (OMER) Receives Buy Rating from HC Wainwright & Co. | OMER Stock News - GuruFocus
HC Wainwright Initiates Coverage on Omeros With Buy Rating, $9 Price Target - MarketScreener
Omeros (OMER) Set for Growth with Potential Narsoplimab Approval - GuruFocus
Omeros (OMER) Set for Growth with Potential Narsoplimab Approval | OMER Stock News - GuruFocus
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program - mx.advfn.com
Omeros (NASDAQ:OMER) Stock Rating Lowered by Wall Street Zen - Defense World
Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026 - mx.advfn.com
OMEROmeros Corporation Reports First Quarter 2025 Financial Results - mx.advfn.com
Squarepoint Ops LLC Has $316,000 Stake in Omeros Co. (NASDAQ:OMER) - Defense World
Millennium Management LLC Buys 27,088 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Two Sigma Advisers LP Decreases Position in Omeros Co. (NASDAQ:OMER) - Defense World
Omeros Corporation to Host Earnings Call - ACCESS Newswire
Nuveen Asset Management LLC Reduces Stock Position in Omeros Co. (NASDAQ:OMER) - Defense World
Omeros Co. (NASDAQ:OMER) Shares Bought by Two Sigma Investments LP - Defense World
Down 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER) - Yahoo Finance
BNP Paribas Financial Markets Has $74,000 Stock Position in Omeros Co. (NASDAQ:OMER) - Defense World
ProShare Advisors LLC Has $183,000 Position in Omeros Co. (NASDAQ:OMER) - Defense World
Omeros Corporation to acquire $80.5 million of its convertible senior notes due 2026 - MSN
Deutsche Bank AG Has $396,000 Stock Holdings in Omeros Co. (NASDAQ:OMER) - Defense World
Omeros' Note Swap Causes Share Price Tumble - Finimize
Omeros: On The Brink As It Awaits Its Fall PDUFA For A Potential Blockbuster (OMER) - Seeking Alpha
Equities Analysts Issue Forecasts for Omeros FY2025 Earnings - Defense World
Omeros Co. (NASDAQ:OMER) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Omeros (NASDAQ:OMER) Rating Increased to Hold at StockNews.com - Defense World
Omeros signals debt reduction of over $100M and prioritizes narsoplimab launch following FDA BLA acceptance - MSN
Omeros (NASDAQ:OMER) Earns Hold Rating from Needham & Company LLC - Defense World
Omeros Corporation (NASDAQ:OMER) Q1 2025 Earnings Call Transcript - Insider Monkey
Omeros Co. (NASDAQ:OMER) Shares Purchased by Comerica Bank - Defense World
Omeros Corp. Earnings Call: Cautious Optimism Amid Challenges - TipRanks
Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic D - GuruFocus
Needham Reiterates Hold Rating on Omeros (OMER) | OMER Stock New - GuruFocus
Earnings call transcript: Omeros Q1 2025 sees stock rise post-earnings By Investing.com - Investing.com Nigeria
Omeros: Q1 Earnings Snapshot - CT Insider
Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ... - Yahoo Finance
Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab Launch Plans - GuruFocus
Omeros (OMER) Achieves Milestone with FDA Acceptance of Narsopli - GuruFocus
Omeros Corporation Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: Omeros Q1 2025 sees stock rise post-earnings - Investing.com
Omeros (OMER) Streamlines Debt, Preps for Narsoplimab Launch - GuruFocus
Transcript : Omeros Corporation, Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
Omeros Corp Q1 2025 Earnings: EPS of -$0.58 Misses Estimates, Re - GuruFocus
Omeros reports Q1 EPS (58c), consensus (60c) - TipRanks
Omeros Corporation Azioni (OMER) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):